Form 4 ABBOTT LABORATORIES For: Feb 28 Filed by: Morrone Louis H.

Go back to Form 4 ABBOTT LABORATORIES For: Feb 28 Filed by: Morrone Louis H.

Evercore ISI Reiterates Outperform Rating on Abbott Labs (ABT), 'a preferential tiering for Libre could position it better for share gains in the larger T2 market'

March 6, 2023 10:19 AM EST

Evercore ISI analyst Vijay Kumar reiterated an Outperform rating and $114.00 price target on Abbott Labs (NYSE: ABT).

The analyst comments "Market opportunity / implications: The T1 market is smalland we would expect ABT to get some incremental share in the T1 market going... More